PRQR (ProQR Therapeutics NV) Shiller PE Ratio: (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRQR ProQR Therapeutics NV PRQR
50 GF Score
Price $1.99
GF Value $2.36
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ProQR Therapeutics NV  (NAS:PRQR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ProQR Therapeutics NV Shiller PE Ratio Related Terms


ProQR Therapeutics NV Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Shiller PE Ratio Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ProQR Therapeutics NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PRQR vs NWBO, IMRX, VNDA: Shiller PE Ratio Comparison

For the Biotechnology subindustry, ProQR Therapeutics NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Shiller PE Ratio falls into.


PRQR
50GF Score
ProQR Therapeutics NV PRQR
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProQR Therapeutics NV Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ProQR Therapeutics NV's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, ProQR Therapeutics NV's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.092/137.7700*137.7700
=-0.092

Current CPI (Jun. 2026) = 137.7700.

ProQR Therapeutics NV Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.483 100.570 -0.662
201612 -0.401 100.710 -0.549
201703 -0.481 101.440 -0.653
201706 -0.528 101.370 -0.718
201709 -0.501 102.030 -0.676
201712 -0.462 101.970 -0.624
201803 -0.407 102.470 -0.547
201806 -0.269 103.100 -0.359
201809 -0.210 103.950 -0.278
201812 -0.375 103.970 -0.497
201903 -0.407 105.370 -0.532
201906 -0.339 105.840 -0.441
201909 -0.341 106.700 -0.440
201912 -0.433 106.800 -0.559
202003 -0.354 106.850 -0.456
202006 -0.090 107.510 -0.115
202009 -0.306 107.880 -0.391
202012 -0.316 107.850 -0.404
202103 -0.298 108.870 -0.377
202106 -0.289 109.670 -0.363
202109 -0.259 110.790 -0.322
202112 -0.294 114.010 -0.355
202203 -0.220 119.460 -0.254
202206 -0.201 119.050 -0.233
202209 -0.327 126.890 -0.355
202212 -0.191 124.940 -0.211
202303 -0.118 124.720 -0.130
202306 -0.108 125.830 -0.118
202309 -0.075 127.160 -0.081
202312 -0.076 126.450 -0.083
202403 -0.098 128.580 -0.105
202406 -0.032 129.910 -0.034
202409 -0.111 131.610 -0.116
202412 -0.094 131.630 -0.098
202503 -0.108 133.330 -0.112
202506 -0.138 133.960 -0.142
202509 -0.117 135.920 -0.119
202512 -0.094 135.270 -0.096
202603 -0.150 136.910 -0.151
202606 -0.092 137.770 -0.092

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is ProQR Therapeutics NV (PRQR) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of $1.99 is trading 15.7% below its estimated GF Value™ of $2.36. GuruFocus considers ProQR Therapeutics NV to be Modestly Undervalued.

Key valuation signals for PRQR:

  • Shiller PE Ratio:
  • GF Value™: $2.36 vs. price of $1.99 (15.7% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the PRQR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ProQR Therapeutics NV Business Description

Other Exchanges 0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score

Get the complete analysis for PRQR

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price
$2.36
GF Value